Blog - Datapharm Australia | Datapharm Australia (2)

Key Considerations When Designing Early-Phase Clinical Trials

Designing early-phase clinical trials is a critical step in the drug development process. These trials, particularly in Phase I and Phase IIa, focus on evaluating the safety, tolerability,...

Understanding the Nuances of Running Early-Phase Oncology Studies

As the landscape of cancer treatment continues to evolve, early-phase oncology studies play a pivotal role in advancing novel therapies from the laboratory to the clinic. These studies, typically...

Considering Pharmacokinetic and Pharmacodynamic Studies in Early-Phase Clinical Trials

Pharmacokinetic (PK) and pharmacodynamic (PD) studies are fundamental components of early-phase clinical trials, particularly in the fields of oncology and other therapeutic areas. These studies...

Clinical Trials in Parkinson's Disease: Considerations and Challenges

Datapharm Australia has previously described why Australia is an attractive location for Sponsors worldwide to conduct clinical trials in Parkinson’s Disease. Read more here.

A Change in Nomenclature to MASLD and MASH

At the 2023 European Association for the Study of the Liver Congress in Vienna, international liver associations introduced new terminology for fatty liver disease, renaming it steatotic liver...

Conducting Wound Healing Clinical Trials in Australia

In Australia, there are more than 450,000 people suffering from chronic wounds each year1. Chronic wounds can have a significant negative impact on the lives of patients and their families. In...

Conducting Inflammatory Bowel Disease Clinical Trials in Australia Part 2

What to consider when designing an IBD clinical trial Inflammatory Bowel Disease (IBD) is a collective term for two chronic, autoimmune diseases of the gastrointestinal tract: ulcerative colitis (UC)...

Conducting Inflammatory Bowel Disease Clinical Trials in Australia Part 1

Inflammatory Bowel Disease (IBD) is a collective term for two chronic, autoimmune diseases of the gastrointestinal tract: ulcerative colitis (UC) and Crohn’s disease (CD). UC causes inflammation and...

Benefits of developing a Risk Management Plan for clinical trials

Introduction A Risk Management Plan (RMP) is a key governance tool for the conduct of clinical trials. It provides a common risk language, an oversight of risk movement, and the ability to make...

Datapharm Australia attends the International Parkinson’s Conference 2024

Datapharm Australia is attending the International Parkinson’s Conference 2024. April is World Parkinson’s Awareness Month, and Datapharm has written a series of blogs discussing the challenges faced...

Meet with Datapharm Australia at BIO SAN-DIEGO 2024

Datapharm Australia is attending the BIO Conference in San Diego. We look forward to connecting with you. To discuss how we can support your local or international clinical trial, contact us today.

Parkinson’s Disease Clinical Trials in Australia

Parkinson's Disease (PD) is one of the fastest growing neurological disorders. With over 10 million people suffering from this disease worldwide, it has become a focus for the clinical research...